All In Biotech

Drug Trial Radar · NCT00000134

Studies of the Ocular Complications of AIDS (SOCA)--Cytomegalovirus Retinitis Retreatment Trial (CRRT)

Cytomegalovirus Retinitis Retreatment Trial

Last checked: Nov 19, 2026Latest source record: Sep 14, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 279 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

279

Actual

Start

Dec 1992

Primary completion

Mar 1995

Study completion Mar 1995

Sponsor

Lead sponsor
Johns Hopkins Bloomberg School of Public HealthAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Eye Institute (NEI); National Institute of Allergy and Infectious Diseases (NIAID); Johns Hopkins University; University of Wisconsin, Madison; Baylor College of Medicine; Tulane University School of Medicine; Icahn School of Medicine at Mount Sinai; New York Presbyterian Hospital; New York University; Northwestern University; University of California, Los Angeles; University of California, San Francisco; University of California, San Diego; University of Miami; University of North Carolina, Chapel Hill; Memorial Sloan Kettering Cancer Center
First posted
Sep 24, 1999

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Factorial
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To compare the relative merits of three therapeutic regimens in patients with AIDS and CMV retinitis who have been previously treated but whose retinitis either is nonresponsive or has relapsed. These three therapeutic regimens were (1) foscarnet, (2) high-dose ganciclovir, and (3) combination foscarnet and ganciclovir. To compare two treatment strategies in patients with relapsed or nonresponsive CMV retinitis: (1) continuing the same anti-CMV drug or (2) switching to the alternate drug.

Conditions

  • HIV Infections
  • Acquired Immunodeficiency Syndrome
  • Cytomegalovirus Retinitis

Interventions

  • GanciclovirDrug

    intravenous ganciclovir induction at 5 mg/kg twice daily for 2 weeks followed by maintenance at 10 mg/kg/day

  • FoscarnetDrug

    intravenous foscarnet induction at 90 mg/kg twice daily for 2 weeks, followed by maintenance therapy at 120 mg/kg/day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MorbidityTime frame: Patients will be seen at baseline, monthly for six months, and then every three months until death or termination of the trial

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.